诺华制药股价下跌超过2.6%,尽管第二季度营收和盈利均有所增长,但新牛皮癣药物Cosentyx的销售额未达预期。此外,公司三种主要药物今年将面临仿制药的竞争压力。
Source LinkDisclaimer: Investing carries risk. This is not financial advice. The above content should not be regarded as an offer, recommendation, or solicitation on acquiring or disposing of any financial products, any associated discussions, comments, or posts by author or other users should not be considered as such either. It is solely for general information purpose only, which does not consider your own investment objectives, financial situations or needs. TTM assumes no responsibility or warranty for the accuracy and completeness of the information, investors should do their own research and may seek professional advice before investing.